Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923115 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
NCT02923115 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 134 participants.
The verdict
NCT02923115, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
Study Summary
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants with acute submassive pulmonary embolism.
Interventions
- DRUG Placebo
- DRUG Enoxaparin
- DRUG DS-1040b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2016-06-23 |
| Est. Completion | 2019-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02923115
The ClinicalTrials.gov registry entry for NCT02923115 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02923115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02923115 about?
NCT02923115 is a clinical study titled "Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism". This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants with acute submassive pulmonary embo...
What is the current status of trial NCT02923115?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2016-06-23. Estimated completion is 2019-08-05.
What interventions are being tested in trial NCT02923115?
The interventions under investigation include: Placebo (DRUG), Enoxaparin (DRUG), DS-1040b (DRUG).
Who is sponsoring clinical trial NCT02923115?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.